Tangeretin suppresses RANKL-induced osteoclastogenesis and alleviates postmenopausal osteoporosis by inhibiting Notch signaling

Background: Postmenopausal osteoporosis is characterized by osteoclast differentiation and bone loss. Tangeretin (TGN) is a natural product that possesses multiple pharmacological properties. However, its specific function in postmenopausal osteoporosis deserves further exploration. Methods: The in...

Full description

Saved in:
Bibliographic Details
Main Authors: Tengfei Wu, Fang Wang, Changqing Ai, Li Li, Fan Wu
Format: Article
Language:English
Published: Elsevier 2025-12-01
Series:Regenerative Therapy
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2352320425000951
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849333857189363712
author Tengfei Wu
Fang Wang
Changqing Ai
Li Li
Fan Wu
author_facet Tengfei Wu
Fang Wang
Changqing Ai
Li Li
Fan Wu
author_sort Tengfei Wu
collection DOAJ
description Background: Postmenopausal osteoporosis is characterized by osteoclast differentiation and bone loss. Tangeretin (TGN) is a natural product that possesses multiple pharmacological properties. However, its specific function in postmenopausal osteoporosis deserves further exploration. Methods: The in vitro and in vivo models of postmenopausal osteoporosis were established by using BMMs stimulated with M-CSF and RANKL and mice receiving ovariectomized (OVX) operation. Osteoclast-specific gene expression was determined by RT-qPCR. The protein level was detected by Western blotting. H&E staining was performed to observe the pathological changes in murine distal femurs. Results: For in vitro study, TGN did not affect cell viability but downregulated RANKL-stimulated osteoclast-specific gene expression. For in vivo study, TGN not only alleviated OVX-triggered pathological alterations of femur tissue, but also effectively inhibited proteoglycan loss and cartilage injury induced by OVX in the femurs of mice. Additionally, TGN prevented osteoclastogenesis in OVX mice by downregulating TRAP activity and osteoclast-specific gene expression. Mechanistically, TGN significantly inhibited the activation of Notch signaling via the downregulation of Notch-1, Notch-2, Notch-3, Jagged1, Hes-1, and Hey-1 protein levels in vitro and in vivo. Conclusion: TGN represses RANKL-induced osteoclastogenesis and alleviates postmenopausal osteoporosis by inhibiting Notch signaling.
format Article
id doaj-art-7e6d3f2ea100400db190cfe3f084f2bc
institution Kabale University
issn 2352-3204
language English
publishDate 2025-12-01
publisher Elsevier
record_format Article
series Regenerative Therapy
spelling doaj-art-7e6d3f2ea100400db190cfe3f084f2bc2025-08-20T03:45:44ZengElsevierRegenerative Therapy2352-32042025-12-013013614310.1016/j.reth.2025.04.019Tangeretin suppresses RANKL-induced osteoclastogenesis and alleviates postmenopausal osteoporosis by inhibiting Notch signalingTengfei Wu0Fang Wang1Changqing Ai2Li Li3Fan Wu4Department of Orthopaedics and Traumatology, Shanghai East Hospital, School of Medicine, Tongji University, No.150 Jimo Road, Pudong New District, Shanghai, ChinaCorresponding author. Shanghai East Hospital, School of Medicine, Tongji University, No.150 Jimo Road, Pudong New District, Shanghai, China.; Department of Orthopaedics and Traumatology, Shanghai East Hospital, School of Medicine, Tongji University, No.150 Jimo Road, Pudong New District, Shanghai, ChinaDepartment of Orthopaedics and Traumatology, Shanghai East Hospital, School of Medicine, Tongji University, No.150 Jimo Road, Pudong New District, Shanghai, ChinaDepartment of Orthopaedics and Traumatology, Shanghai East Hospital, School of Medicine, Tongji University, No.150 Jimo Road, Pudong New District, Shanghai, ChinaDepartment of Orthopaedics and Traumatology, Shanghai East Hospital, School of Medicine, Tongji University, No.150 Jimo Road, Pudong New District, Shanghai, ChinaBackground: Postmenopausal osteoporosis is characterized by osteoclast differentiation and bone loss. Tangeretin (TGN) is a natural product that possesses multiple pharmacological properties. However, its specific function in postmenopausal osteoporosis deserves further exploration. Methods: The in vitro and in vivo models of postmenopausal osteoporosis were established by using BMMs stimulated with M-CSF and RANKL and mice receiving ovariectomized (OVX) operation. Osteoclast-specific gene expression was determined by RT-qPCR. The protein level was detected by Western blotting. H&E staining was performed to observe the pathological changes in murine distal femurs. Results: For in vitro study, TGN did not affect cell viability but downregulated RANKL-stimulated osteoclast-specific gene expression. For in vivo study, TGN not only alleviated OVX-triggered pathological alterations of femur tissue, but also effectively inhibited proteoglycan loss and cartilage injury induced by OVX in the femurs of mice. Additionally, TGN prevented osteoclastogenesis in OVX mice by downregulating TRAP activity and osteoclast-specific gene expression. Mechanistically, TGN significantly inhibited the activation of Notch signaling via the downregulation of Notch-1, Notch-2, Notch-3, Jagged1, Hes-1, and Hey-1 protein levels in vitro and in vivo. Conclusion: TGN represses RANKL-induced osteoclastogenesis and alleviates postmenopausal osteoporosis by inhibiting Notch signaling.http://www.sciencedirect.com/science/article/pii/S2352320425000951Postmenopausal osteoporosisTGNOsteoclast differentiationNotch signaling
spellingShingle Tengfei Wu
Fang Wang
Changqing Ai
Li Li
Fan Wu
Tangeretin suppresses RANKL-induced osteoclastogenesis and alleviates postmenopausal osteoporosis by inhibiting Notch signaling
Regenerative Therapy
Postmenopausal osteoporosis
TGN
Osteoclast differentiation
Notch signaling
title Tangeretin suppresses RANKL-induced osteoclastogenesis and alleviates postmenopausal osteoporosis by inhibiting Notch signaling
title_full Tangeretin suppresses RANKL-induced osteoclastogenesis and alleviates postmenopausal osteoporosis by inhibiting Notch signaling
title_fullStr Tangeretin suppresses RANKL-induced osteoclastogenesis and alleviates postmenopausal osteoporosis by inhibiting Notch signaling
title_full_unstemmed Tangeretin suppresses RANKL-induced osteoclastogenesis and alleviates postmenopausal osteoporosis by inhibiting Notch signaling
title_short Tangeretin suppresses RANKL-induced osteoclastogenesis and alleviates postmenopausal osteoporosis by inhibiting Notch signaling
title_sort tangeretin suppresses rankl induced osteoclastogenesis and alleviates postmenopausal osteoporosis by inhibiting notch signaling
topic Postmenopausal osteoporosis
TGN
Osteoclast differentiation
Notch signaling
url http://www.sciencedirect.com/science/article/pii/S2352320425000951
work_keys_str_mv AT tengfeiwu tangeretinsuppressesranklinducedosteoclastogenesisandalleviatespostmenopausalosteoporosisbyinhibitingnotchsignaling
AT fangwang tangeretinsuppressesranklinducedosteoclastogenesisandalleviatespostmenopausalosteoporosisbyinhibitingnotchsignaling
AT changqingai tangeretinsuppressesranklinducedosteoclastogenesisandalleviatespostmenopausalosteoporosisbyinhibitingnotchsignaling
AT lili tangeretinsuppressesranklinducedosteoclastogenesisandalleviatespostmenopausalosteoporosisbyinhibitingnotchsignaling
AT fanwu tangeretinsuppressesranklinducedosteoclastogenesisandalleviatespostmenopausalosteoporosisbyinhibitingnotchsignaling